Trials / Completed
CompletedNCT03652493
Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
Multicentre, Open-label Phase 2 Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Centre Francois Baclesse · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators propose a phase II study to evaluate the efficacy of carboplatin monotherapy in the tumor subgroup of metastatic castration-resistant prostatic carcinomas with somatic abnormality in the Homologous Recombination (HR) pathway. This study may also better characterize the molecular abnormalities of tumors required for the carboplatin response
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Carboplatin | Tumoral evaluation every 3 cycles |
Timeline
- Start date
- 2018-09-10
- Primary completion
- 2021-04-27
- Completion
- 2021-05-21
- First posted
- 2018-08-29
- Last updated
- 2025-10-06
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03652493. Inclusion in this directory is not an endorsement.